Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Differentiated Thyroid Cancer
100%
Tumor
100%
Radioiodine Therapy
88%
Papillary Thyroid Cancer
88%
Epidermal Growth Factor Receptor
88%
Cancer Cell
88%
Lenvatinib
88%
Gefitinib
39%
Promoter Region
33%
IC50
29%
Metastatic Carcinoma
22%
Primary Tumor
22%
Radioactive Iodine
22%
Molecular Marker
22%
Cell Line
19%
Gene Expression
19%
Diseases
11%
Systemic Therapy
11%
Thyroglobulin
11%
Next Generation Sequencing
11%
Progression Free Survival
11%
Treatment Response
11%
Monotherapy
9%
Protein Kinase B
9%
In Vitro
9%
Comparative Genomic Hybridization
9%
Cell Viability
9%
Clonogenic Assay
9%
Thyroid Cancer
9%
Colony Formation
9%
Mitogen Activated Protein Kinase 3
9%
extracellular signal regulated kinase
9%
Keyphrases
Therapy Outcome
88%
Radioiodine Therapy
88%
Clinical Characterization
88%
Molecular Characterization
88%
Advanced Differentiated Thyroid Cancer
88%
Papillary Thyroid Cancer
55%
BCPAP
44%
Thyroid Patients
33%
Metastatic Lesions
22%
Distant Metastasis
22%
TERT Promoter mutation
22%
Radioiodine
22%
Primary Tumor
22%
Molecular Markers
22%
Ptc1
22%
Systemic Therapy
11%
Clinical Markers
11%
Therapy Response
11%
Progression Rate
11%
Early Identification
11%
Median Estimation
11%
Non-associated
11%
Cancer Subtypes
11%
Disease Progression
11%
Retrospective Analysis
11%
Tumor Samples
11%
Stimulated Thyroglobulin
11%
Metastatic Disease
11%
BRAF V600E
11%
Metastatic Thyroid Cancer
11%
Next-generation Sequencing
11%
TERT Promoter
11%
Progression-free Survival
11%
Lenvatinib Resistance
11%
EGFR Expression
11%
EGFR-targeting
11%
MAPK Signaling
11%
Adaptive Resistance
11%
Pharmacology, Toxicology and Pharmaceutical Science
Differentiated Thyroid Cancer
88%
Epidermal Growth Factor Receptor
88%
Lenvatinib
88%
Gefitinib
39%
IC50
29%
Protein Kinase B
9%
Monotherapy
9%
Mitogen Activated Protein Kinase 3
9%
Intrinsic Resistance
9%
Cell Viability
9%
Viability Assay
9%
Thyroid Cancer
9%